Molecular Screening and Therapeutics (MoST) study

Stage 1
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour, we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.

A team of experts review the molecular profile of the tumour with other clinical and patient information. A report is provided to the referring clinician.

Stage 2
Patients identified as possessing any of a range of molecular characteristics (identified during Stage 1) may be eligible to access treatment in a MoST therapeutic study (a clinical trial) or other targeted therapy.

Pan cancer subprogram: Patients aged 16 years and older with an advanced and/or metastatic solid or blood cancer with limited treatment options, and who are willing and fit enough to participate in a clinical trial, are eligible.

Lung cancer subprogram: Patients aged 18 years and older with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSCLC), who have not had any previous treatment for the lung cancer and who are willing and fit enough to participate in a clinical trial, are eligible.

Your treating oncologist will assess your eligibility, complete the MoST referral forms, and provide all relevant information.

For patients

• Discussing the study with the MoST team (either by telephone or face-to-face)
• Consenting to the access of samples held by pathology centres
• Consenting to the access of their medical records
• Donating a blood sample
• Completing questionnaires
• Providing optional consent for access to Medicare/PBS data